Cargando…

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

Triple negative tumors represent 15% of breast cancer and are characterized by the lack of estrogen receptors, progesterone receptor, and HER2 amplification or overexpression. Approximately 25% of patients diagnosed with triple negative breast cancer carry a germline BRCA1 or BRCA2 mutation. They ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barchiesi, Giacomo, Roberto, Michela, Verrico, Monica, Vici, Patrizia, Tomao, Silverio, Tomao, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655309/ https://www.ncbi.nlm.nih.gov/pubmed/34900718 http://dx.doi.org/10.3389/fonc.2021.769280

Ejemplares similares

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Triple-negative breast cancer: new perspectives for targeted therapies
por: Tomao, Federica, et al.
Publicado: (2015)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets
por: Roberto, Michela, et al.
Publicado: (2023)

Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach
por: Tomao, Federica, et al.
Publicado: (2013)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
por: Marinelli, Daniele, et al.
Publicado: (2020)

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice
por: Roberto, Michela, et al.
Publicado: (2021)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Immunologic treatments for precancerous lesions and uterine cervical cancer
por: Vici, Patrizia, et al.
Publicado: (2014)

Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
por: Rossi, Luigi, et al.
Publicado: (2013)

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Liu, Xu, et al.
Publicado: (2021)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
por: Tomao, Silverio, et al.
Publicado: (2006)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Breast cancer metastatic to the pituitary gland: a case report
por: Spinelli, Gian Paolo, et al.
Publicado: (2012)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Fertility drugs, reproductive strategies and ovarian cancer risk
por: Tomao, Federica, et al.
Publicado: (2014)

The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
por: Roberto, Michela, et al.
Publicado: (2023)

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report
por: Gozzi, Elisa, et al.
Publicado: (2020)

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
por: Rossi, Luigi, et al.
Publicado: (2013)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art
por: Feola, Tiziana, et al.
Publicado: (2022)

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
por: Di Lisa, Francesca Sofia, et al.
Publicado: (2023)

Colorectal cancer metastatic to the breast: A case report
por: Taccogna, Silvia, et al.
Publicado: (2020)

Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
por: Miele, Evelina, et al.
Publicado: (2008)

A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario
por: Nahvi, Insha, et al.
Publicado: (2022)

Investigating Molecular Profiles of Ovarian Cancer: An Update on Cancer Stem Cells
por: Tomao, Federica, et al.
Publicado: (2014)

Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions
por: Takanen, Silvia, et al.
Publicado: (2022)

Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
por: Geurts, Veerle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kbaj3njbevr1cmd39rhr9e2340